Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642 1671 1672
This examiner grants 32% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18308349 | METHODS FOR IMPROVING COVID VACCINE IMMUNOGENICITY | Non-Final OA | Northwestern University |
| 18274641 | FC-ENHANCED ANTIBODIES FOR PREVENTION AND TREATMENT OF EBOLA VIRUS INFECTION | Non-Final OA | The General Hospital Corporation |
| 18294775 | SYNERGISM OF IMMUNOGENICITY VIA COMBINED PARENTERAL AND MUCOSAL IMMUNIZATION AGAINST COVID-19 | Non-Final OA | BHARAT BIOTECH INTERNATIONAL LIMITED |
| 18427625 | METHODS AND COMPOSITIONS FOR QUADRIVALENT INFLUENZA VACCINE | Non-Final OA | Arcturus Therapeutics, Inc. |
| 18283596 | VIRAL CLEARANCE TEST METHOD | Non-Final OA | ASAHI KASEI LIFE SCIENCE CORPORATION |
| 18317421 | PRIMERS, KIT AND METHOD FOR DETECTING OF AFRICAN SWINE FEVER VIRUS | Non-Final OA | ARMY MEDICAL UNIVERSITY |
| 17639023 | METHOD AND DEVICE FOR PATHOGEN OR ANTIBODY DETECTION USING UNMODIFIED SIGNALING SUBSTANCES WITH OR WITHOUT UNLABELED DETECTION REAGENTS | Final Rejection | NANO DISCOVERY INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy